Investor Centre

Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has received approval for simplified access to Bronchitol® for the treatment of cystic fibrosis (CF) under the Australian government’s  Pharmaceutical Benefits Scheme (PBS) in a decision that brings criteria for reimbursement in line with current clinical practice.

Pharmaxis has been advised of a positive decision on its application to the Pharmaceutical Benefits Advisory Committee (PBAC) to change the wording of the PBS listing for Bronchitol, removing a requirement for patients to demonstrate a 10% increase in a spirometric measure of lung function in order to secure continued PBS reimbursement.

Pharmaceutical company Pharmaxis (ASX:PXS) today announced that two of its research projects conducted in conjunction with the University of Sydney have been awarded funding under the Australian Research Council (ARC) Linkage Projects scheme.

Leading Australian renal physician Professor Carol Pollock is heading an investigation of the utility of Pharmaxis compound PXS-4728A in treating renal fibrosis, while in a separate project  Associate Professors Paul Young and Daniela Traini, and Dr Brian Oliver will work on developing  advanced inhalation technology to deliver  Pharmaxis’ compounds to underlying fibrotic cells in the lung.

The ARC Scheme will provide funding of $405,646 and $370,000 for the two projects respectively, over three years which will match expenditure by Pharmaxis.